Today ANTH ranks # as SELL CANDIDATE.
Today ANTH ranks # as SELL CANDIDATE.

ANTH stock Anthera Pharmaceuticals

ANTH stock
Anthera Pharmaceuticals

April 24, 2019
Change 2.58%
Chart period: 2019-01-25 - 2019-04-24





Will ANTH stock price go up or down on Thu, 25 Apr 2019?

Anthera Pharmaceuticals Forecast and Stock Analysis

Technical ANTH stock analysis for April 24, 2019.

Sell candidate since 2019-04-18 Gain 2.58%
Shorts 2.04% ( 2018-06-15 )
Cash 17.2 mill
Loans n/a
Beta 2.73
ROA -138.08

Anthera Pharmaceuticals gained 2.58% in the last trading day, rising from $0.09 to $0.09 The price has been going up and down for this period, and there has been a -2.82% loss for the last 2 weeks. Volume fell in the last day by -141 272 shares, and in total, 33 662 shares bought and sold for approximately $3 107.68. You should take into consideration that a falling volume on higher prices causes divergence and may be an early warning about possible changes for the next couple of days.

Close price at the end of the last trading day (Wednesday, 24th Apr 2019) of the ANTH stock was $0.09. This is 2.58% more than the trading day before Tuesday, 23rd Apr 2019.

During day the stock fluctuated 22.27% from a day low at $0.08 to a day high of $0.10.

30 day high of the ANTH stock price was $0.10 and low was $0.07.
90 day high was $0.10 and low was $0.05.
52 week high for the Anthera Pharmaceuticals - $0.40 and low - $0.01.


Anthera Pharmaceuticals lies in the middle of a very wide and strong rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the stock is expected to rise 15.67% during the next 3 months and, with 90% probability hold a price between $0.10 and $0.13 at the end of this period.

Click here for today's Top 5 Trending Companies


A buy signal was issued from a pivot bottom point on Tuesday April 23, 2019, which indicates further gains until a new top pivot has been found. Some negative signals were issued as well, and these may have some influence on the near short-term development. Anthera Pharmaceuticals holds a buysignal from the short-term moving average; at the same time, however, a sales signal from the long-term average. Since the longterm average is above the short-term average there is a general sales signal in the stock. On further gains, the stock will meet resistance from the long-term moving average at $0.10. On a fall, the stock will find some support from the short-term average at $0.09. A break-up through the long-term average will give another buy signal, while a fall below the short-term average will add another sales signal and strengthen the general signal. Volume fell during the last trading day while the price increased. This causes a divergence and may be considered as an early warning, but it may not be. The very low volume increases the risk and reduces the other technical signals issued.

Access today's Top 5 Golden Star Companies

A buy signal from a double bottom formation was found on Tuesday April 23, 2019 and based on theory for this formation the price should go up by 0.01% to $0.10 within 2 trading days since signal was issued (Thursday April 25, 2019).

Relative Strength Index (RSI)

RSI14 is 46 and the stock is currently not being overbought or oversold

Access full RSI 14 and RSI 21 lists

Support & Resistance

Anthera Pharmaceuticals finds support from accumulated volume at $0.09.

Support: $0.09 Price: $0.09 Resistance: $0.10


This stock may move much during a day (volatility) and with periodic low trading volume this stock is considered to be "high risk". During the last day, the stock moved $0.02 between high and low, or 22.27%. For the last week the stock has had a daily average volatility of 25.64%.

Our recommended stoploss: We hold a sell evaluation for this stock. No stop-loss set.

Overall risk:

Very Low Low Medium High Very High

Evaluation: Sell Candidate

Anthera Pharmaceuticals holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock. We have upgraded our recommendation for this stock since last evaluation from a Strong Sell Candidate to a Sell Candidate.

Today ANTH ranks # as SELL CANDIDATE.
Today ANTH ranks # as SELL CANDIDATE.